Jane Street’s Vaxcyte PCVX Stock Holding History

Jane Street’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.7M	Buy	234,900 +230,000	+4,694%	+$12.5M	﹤0.01%	2162
2025 Q4	$226K	Sell	4,900 -71,300	-94%	-$3.19M	﹤0.01%	9476
2025 Q3	$2.74M	Buy	76,200 +57,200	+301%	+$1.9M	﹤0.01%	4376
2025 Q2	$618K	Sell	19,000 -32,400	-63%	-$1.06M	﹤0.01%	6539
2025 Q1	$1.94M	Buy	51,400 +15,900	+45%	+$1.27M	﹤0.01%	4401
2024 Q4	$2.91M	Sell	35,500 -37,700	-52%	-$3.74M	﹤0.01%	3506
2024 Q3	$8.36M	Buy	73,200 +59,300	+427%	+$5.34M	﹤0.01%	2121
2024 Q2	$1.05M	Sell	13,900 -3,500	-20%	-$238K	﹤0.01%	5670
2024 Q1	$1.19M	Buy	17,400 +6,800	+64%	+$471K	﹤0.01%	5090
2023 Q4	$666K	Buy	+10,600	New	+$551K	﹤0.01%	6280
2023 Q2	–	Sell	-11,800	Closed	-$442K	–	9341
2023 Q1	$442K	Sell	11,800 -43,500	-79%	-$1.85M	﹤0.01%	6523
2022 Q4	$2.65M	Buy	+55,300	New	+$2.17M	﹤0.01%	3406

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's PCVX Position: Q1 2026 in Review

Jane Street reduced its Vaxcyte (PCVX) stake by 9.6% in Q1 2026, selling an estimated $1.45M and leaving 252,877 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Jane Street first reported a position in PCVX in Q2 2020 and has held it in 15 quarters since. The position peaked at $24.5M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Jane Street held 252,877 shares of Vaxcyte worth $14.7M as of Q1 2026.
Jane Street sold 26,727 Vaxcyte shares in Q1 2026, an estimated $1.45M.
Vaxcyte made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2084 holding.
Jane Street first reported a position in Vaxcyte in Q2 2020 and has held it in 15 quarters since.
Jane Street's Vaxcyte position peaked at $24.5M in Q4 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.